(updated - 08 Feb 2012)
Stock Updates
Suven secures 3 product patents for NCEs in Mexico, US
Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but does not warrant or guarantee their accuracy or date.
Our site takes no responsibility for any investment decisions based on recommendations provided on website.
Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to to our website and any financial deal should be done on their own sole responsibility.
More News Follows
Suven Life Sciences (Suven) today announced the grant of three product patents, two from USA and one from Mexico corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2025 and 2028.
The granted claims of thr patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with Neurodegenerative disorders like Alzheimer`s disease, Attention deficient hyperractivity disorder (ADFD), Huntington`s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of eleven granted patents from USA and twelve granted patents from Mexico.